油性对比剂在子宫输卵管造影中的疗效与疼痛相关:H2Oil随机试验的事后分析
该研究为H2Oil随机对照试验的事后分析,评估子宫输卵管造影(HSG)时疼痛程度和对比剂用量是否影响油性对比剂的疗效。在400名报告疼痛评分的女性中,疼痛与持续妊娠存在显著交互作用(P=0.047);疼痛VAS≥6的女性使用油性对比剂6个月持续妊娠率高于水性对比剂(49.4% vs 29.6%;RR 1.7;95%CI 1.1-2.5),而VAS≤5者无显著差异。对比剂用量未改变油性对比剂的疗效(交互作用P=0.23)。
要点
- HSG时疼痛VAS≥6的不孕女性,油性对比剂6个月持续妊娠率显著高于水性对比剂。
- 疼痛VAS≤5者,油性与水性对比剂的持续妊娠率无显著差异。
- 对比剂用量未显著影响油性对比剂对持续妊娠的效应。
核心结论
- 在HSG中报告中度至重度疼痛的女性,使用油性对比剂相比水性对比剂可获得更多持续妊娠。
- 在报告轻度或无疼痛的女性中,油性与水性对比剂的持续妊娠率无差异。
- 对比剂用量未改变油性对比剂对持续妊娠的效应。
研究设计与样本
- H2Oil多中心随机对照试验的事后分析,评估油性与水性对比剂在HSG中的治疗效应。
- 400名女性报告了HSG期间疼痛(视觉模拟量表VAS,范围0.0-10.0 cm),512名女性记录了对比剂用量(毫升)。
- 采用逻辑回归分析,按意向性治疗原则分析数据。
主要发现
- 400名女性总体中位疼痛评分5.0(IQR 3.0-6.8);油性组(n=199)4.8(IQR 3.0-6.4),水性组(n=201)5.0(IQR 3.0-6.7),P=0.28。
- 疼痛(VAS≤5 vs VAS≥6)与主要结局持续妊娠存在显著交互作用(P=0.047)。
- VAS≥6女性中,油性对比剂6个月持续妊娠率49.4% vs 水性29.6%(RR 1.7;95%CI 1.1-2.5)。
- VAS≤5女性中,油性对比剂6个月持续妊娠率28.8% vs 水性29.2%(RR 0.99;95%CI 0.66-1.5)。
- 512名女性中,油性组中位对比剂用量9.0 ml(IQR 5.7-15.0),水性组8.0 ml(IQR 5.9-13.0),P=0.72;用量与油性对比剂效应的交互作用P=0.23。
临床怎么用
- 对于HSG时报告中度至重度疼痛(VAS≥6)的不孕女性,可优先考虑使用油性对比剂以改善持续妊娠率。
- 对于HSG时疼痛轻微或无痛(VAS≤5)的女性,油性与水性对比剂的持续妊娠率无显著差异,选择需个体化。
局限性
- 本研究为事后分析,应视为假设生成性研究。
- 原随机对照试验仅纳入排卵性不孕、年龄小于39岁且输卵管病变低风险的女性,结果不应推广至不符合这些特征的不孕女性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
STUDY QUESTION: Does pain or volume of used contrast medium impact the effectiveness of oil-based contrast during hysterosalpingography (HSG)? SUMMARY ANSWER: In women who report moderate to severe pain during HSG, the use of oil-based contrast resulted in more ongoing pregnancies compared to the use of water-based contrast, whereas in women who reported mild or no pain, no difference in ongoing pregnancies was found. WHAT IS KNOWN ALREADY: We recently showed that in infertile women undergoing HSG, the use of oil-based contrast results in more ongoing pregnancies within 6 months as compared to the use of water-based contrast. However, the underlying mechanism of this fertility-enhancing effect remains unclear. STUDY DESIGN, SIZE, DURATION: We performed a post-hoc analysis of the H2Oil study, a multicentre randomised controlled trial (RCT) evaluating the therapeutic effect of oil- and water-based contrast at HSG. Here, we evaluated the impact of pain experienced at HSG and volume of used contrast media during HSG on ongoing pregnancy. PARTICIPANTS/MATERIALS, SETTING, METHODS: In a subset of 400 participating women, pain during HSG by means of the Visual Analogue Scale (VAS) (range: 0.0-10.0 cm) was reported, while in 512 women, we registered the volume of used contrast (in millilitres). We used logistic regression analyses to assess whether pain and volume of used contrast media modified the effect of oil-based contrast on ongoing pregnancy rates. Data were analysed according to intention-to-treat principle. MAIN RESULTS AND THE ROLE OF CHANCE: In 400 women in whom pain scores were reported, the overall median pain score was 5.0 (Interquartile range (IQR) 3.0-6.8) (oil group (n = 199) 4.8 (IQR 3.0-6.4); water group (n = 201) 5.0 (IQR 3.0-6.7); P-value 0.28). There was a significant interaction between pain (VAS ≤5 versus VAS ≥6) and the primary outcome ongoing pregnancy (P-value 0.047). In women experiencing pain (VAS ≥6), HSG with oil-based contrast resulted in better 6-month ongoing pregnancy rates compared to HSG with water-based contrast (49.4% versus 29.6%; RR 1.7; 95% CI, 1.1-2.5), while in women with a pain score ≤5, 6-month ongoing pregnancy rates were not significantly different between the use of oil- (28.8%) versus water-based contrast (29.2%) (RR 0.99; 95% CI, 0.66-1.5). In the 512 women in whom we recorded contrast, median volume was 9.0 ml (IQR 5.7-15.0) in the oil group versus 8.0 ml (IQR 5.9-13.0) in the water group, respectively (P-value 0.72). Volume of used contrast was not found to modify the effect of oil-based contrast on ongoing pregnancy (P-value for interaction 0.23). LIMITATIONS, REASONS FOR CAUTION: This was a post-hoc analysis that should be considered as hypothesis generating. The RCT was restricted to infertile ovulatory women, younger than 39 years of age and with a low risk for tubal pathology. Therefore, our results should not be generalised to infertile women who do not share these features. WIDER IMPLICATIONS OF THE FINDINGS: The underlying mechanism of the fertility-enhancing effect induced by HSG with the use of oil-based contrast remains unclear. However, these findings suggest a possible mechanistic pathway, that is increasing intrauterine pressure occurring prior to dislodging pregnancy hindering debris or mucus plugs from the proximal part of otherwise normal fallopian tubes. This information might help in the search of the underlying fertility-enhancing mechanism found by using oil-based contrast during HSG. STUDY FUNDING/COMPETING INTEREST(S): The original H2Oil RCT was an investigator-initiated study that was funded by the two academic institutions (AMC and VUmc) of the Amsterdam UMC. The funders had no role in study design, collection, analysis and interpretation of the data. K.D. reports consultancy for Guerbet. H.V. reports consultancy fees from Ferring. C.B.L. reports speakers' fees from Ferring and research grants from Ferring, Merck and Guerbet. V.M. reports receiving travel and speakers fees as well as research grants from Guerbet. B.W.M. is supported by an NHMRC Practitioner Fellowship (GNT1082548). B.W.M. reports consultancy for ObsEva, Merck KGaA and Guerbet and travel and research grants from Merck KGaA and Guerbet. The other authors do not report conflict of interests. TRIAL REGISTRATION NUMBER: The H2Oil study was registered at the Netherlands Trial Registry (NTR 3270). TRIAL REGISTRATION DATE: 1 February 2012. DATE OF FIRST PATIENT’S ENROLMENT: 3 February 2012.
引用
- van Welie N, Dreyer K, van Rijswijk J, et al. Treatment effect of oil-based contrast is related to experienced pain at HSG: a post-hoc analysis of the randomised H2Oil study. Hum Reprod. 2019. PMID: 31887222. doi:10.1093/humrep/dez206
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。